Medtronic (NYSE:MDT) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Medtronic (NYSE:MDT) from a hold rating to a buy rating in a research note issued to investors on Saturday morning.

Other equities analysts also recently issued reports about the stock. Daiwa Securities Group cut their price target on shares of Medtronic from $117.00 to $115.00 and set a “buy” rating on the stock in a report on Friday, February 27th. JPMorgan Chase & Co. lowered their price objective on shares of Medtronic from $105.00 to $100.00 and set a “neutral” rating on the stock in a research report on Wednesday, February 18th. Weiss Ratings reiterated a “buy (b-)” rating on shares of Medtronic in a research note on Monday, December 29th. Needham & Company LLC reissued a “buy” rating and set a $120.00 target price on shares of Medtronic in a research report on Thursday, March 26th. Finally, UBS Group restated a “neutral” rating and set a $104.00 price target on shares of Medtronic in a research note on Wednesday, February 4th. One equities research analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating and ten have assigned a Hold rating to the stock. According to MarketBeat.com, Medtronic presently has a consensus rating of “Moderate Buy” and a consensus price target of $110.74.

Medtronic Stock Performance

Shares of MDT opened at $85.75 on Friday. The stock has a 50 day moving average of $95.58 and a 200 day moving average of $96.46. The company has a market capitalization of $110.09 billion, a price-to-earnings ratio of 23.89, a PEG ratio of 2.24 and a beta of 0.71. Medtronic has a 12 month low of $79.55 and a 12 month high of $106.33. The company has a current ratio of 2.54, a quick ratio of 1.87 and a debt-to-equity ratio of 0.57.

Medtronic (NYSE:MDT) last posted its quarterly earnings data on Tuesday, February 17th. The medical technology company reported $1.36 earnings per share for the quarter, topping the consensus estimate of $1.34 by $0.02. The business had revenue of $9.02 billion for the quarter, compared to analysts’ expectations of $8.89 billion. Medtronic had a return on equity of 14.82% and a net margin of 13.00%.The business’s revenue was up 5.8% on a year-over-year basis. During the same quarter in the previous year, the firm earned $1.38 earnings per share. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. As a group, sell-side analysts forecast that Medtronic will post 5.46 earnings per share for the current year.

Medtronic Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, April 17th. Shareholders of record on Friday, March 27th will be issued a dividend of $0.71 per share. The ex-dividend date of this dividend is Friday, March 27th. This represents a $2.84 annualized dividend and a yield of 3.3%. Medtronic’s dividend payout ratio is 79.11%.

Insiders Place Their Bets

In other news, EVP Harry Skip Kiil sold 52,524 shares of Medtronic stock in a transaction dated Thursday, February 19th. The shares were sold at an average price of $97.71, for a total value of $5,132,120.04. Following the completion of the transaction, the executive vice president owned 32,768 shares in the company, valued at $3,201,761.28. This trade represents a 61.58% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 0.26% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the business. Delos Wealth Advisors LLC bought a new position in shares of Medtronic in the second quarter worth $27,000. Corundum Trust Company INC purchased a new position in shares of Medtronic in the third quarter valued at $27,000. Lodestone Wealth Management LLC bought a new stake in shares of Medtronic during the 4th quarter valued at $27,000. Anfield Capital Management LLC raised its stake in shares of Medtronic by 410.7% during the 4th quarter. Anfield Capital Management LLC now owns 286 shares of the medical technology company’s stock valued at $27,000 after purchasing an additional 230 shares during the period. Finally, Monetary Solutions Ltd purchased a new stake in Medtronic during the 4th quarter worth about $27,000. 82.06% of the stock is owned by institutional investors.

Medtronic Company Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).